3-(2-氟乙氧基)苄胺 | 1037078-87-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-氟乙氧基)苄胺
• 英文名称: 3-(2-fluoroethoxy)benzylamine
• 英文别名: [3-(2-fluoroethoxy)phenyl]methanamine
• CAS: 1037078-87-7
• 化学式: C₉H₁₂FNO
• 分子量: 169.199
• InChiKey: VHAGHBKALUHQOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  12
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  35.2
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(2-氟乙氧基)苄胺 、 2,6-dichloro-9-((3aR,3bR,4aS,5R,5aS)-2,2-dimethylhexahydrocyclopropa[3,4]cyclopenta[1,2-d][1,3]dioxol-5-yl)-9H-purine 在 三乙胺 作用下， 以 甲醇 为溶剂， 以84%的产率得到(1R,2R,3S,4R,5S)-4-(2-chloro-6-(3-(2-fluoroethoxy)benzylamino)-9H-purin-9-yl)-2',3'-O-(isopropylidene)-bicycle[3.1.0]hexane
  参考文献：
  名称：

  Truncated (N)-Methanocarba Nucleosides as A₁ Adenosine Receptor Agonists and Partial Agonists: Overcoming Lack of a Recognition Element

  摘要：

  A(1) adenosine receptor (AR) agonists are neuroprotective, cardioprotective, and anxiolytic. (N)-Methanocarba adenine nucleosides designed to bind to human A(1)AR were truncated to eliminate 5'-CH2OH. This modification previously converted A(3)AR agonists into antagonists, but the comparable effect at A(1)AR is unknown. In comparison to ribosides, affinity at the A(1)AR was less well preserved than that at the A(3)AR, although a few derivatives were moderately A(1)AR selective, notably full agonist 21 (N-6-dicyclopropyl-methyl, K-i 47.9 nM). Thus, at the A(1)AR, recognition elements for nucleoside binding depend more on 5' region interactions, and in their absence, A(3)AR selectivity predominates. Based on the recently reported agonist-bound AR structure, this difference between subtypes likely correlates with an essential His residue in transmembrane domain 6 of A(1) but not A(3)AR The derivatives ranged from partial to full agonists in A(1)AR-mediated adenylate cyclase inhibition. Truncated derivatives have more druglike physical properties than other A(1)AR agonists; this approach is appealing for preclinical development.

  DOI：

  10.1021/ml200114q
• 作为产物：
  描述：

  3-(2-fluoroethoxy)benzonitrile 在 lithium aluminium tetrahydride 、 sodium hydroxide 、 水 作用下， 以 四氢呋喃 为溶剂， 反应 1.83h， 以100%的产率得到3-(2-氟乙氧基)苄胺
  参考文献：
  名称：

  WO2008/83056

  摘要：

  公开号：

文献信息

• LIGANDS FOR IMAGING CARDIAC INNERVATION
  申请人：Purohit Ajay

  公开号：US20100221182A1

  公开（公告）日：2010-09-02

  Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18 F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

  本发明揭示了一种新型化合物，可用作核医学应用（PET成像）中的成像剂，用于成像心脏神经。这些基于PET的放射性示踪剂可能表现出增加的稳定性，减少NE释放（从而减少副作用），改善定量数据和/或高亲和力，以VMAT优于先前的放射性示踪剂。还提供了使用这些化合物成像心脏神经的方法。在某些情况下，这些化合物是通过在各种位置上衍生化某些化合物与18F而开发出来的：芳基，烷基，酮，苄基，β-烷基醚，γ-丙基烷基醚和β-丙基烷基醚。或者，还可以添加甲基基团到胺中，和/或消除或掩盖儿茶酚的功能，以使这些化合物更加稳定。
• Ligands for imaging cardiac innervation
  申请人：Lantheus Medical Imaging, Inc.

  公开号：EP2474523A2

  公开（公告）日：2012-07-11

  Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with 18F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.

  本研究公开了在核医学应用（PET 成像）中用作心脏神经支配成像剂的新型化合物。这些基于 PET 的放射性racer 与之前的放射性racer 相比，可表现出更高的稳定性、更少的 NE 释放（从而减少副作用）、更好的定量数据和/或对 VMAT 的高亲和力。还提供了使用这些化合物对心脏神经支配进行成像的方法。在某些情况下，这些化合物是通过在芳基、烷基、酮基、苄基、β-烷基醚、γ-丙基烷基醚和β-丙烯基烷基醚等不同位置上用 18F 对某些化合物进行衍生而得到的。另外，还可以在胺中加入甲基，和/或消除或掩盖儿茶酚官能团，使这些化合物更加稳定。
• N-[3-BROMO-4-(3- [18F]FLUOROPROPOXY)-BENZYL]-GUANIDINE FOR IMAGING CARDIAC INNERVATION
  申请人：Lantheus Medical Imaging, Inc.

  公开号：EP2114873B1

  公开（公告）日：2013-02-20
• US8491868B2
  申请人：——

  公开号：US8491868B2

  公开（公告）日：2013-07-23
• [EN] LIGANDS FOR IMAGING CARDIAC INNERVATION<br/>[FR] LIGANDS POUR IMAGERIE D'INNERVATION CARDIAQUE
  申请人：BRISTOL MYERS SQUIBB PHARMA CO

  公开号：WO2008083056A2

  公开（公告）日：2008-07-10

  [EN] Novel compounds that find use as imaging agents within nuclear medicine applications (PET imaging) for imaging of cardiac innervation are disclosed. These PET based radiotracers may exhibit increased stability, decreased NE release (thereby reducing side effects), improved quantitative data, and/or high affinity for VMAT over prior radiotracers. Methods of using the compounds to image cardiac innervation are also provided. In some instances the compounds are developed by derivatizing certain compounds with ¹⁸F in a variety of positions: aryl, alkyl, a keto, benzylic, beta-alkylethers, gamma-propylalkylethers and beta-proplylalkylethers. Alternatively or additionally, a methyl group a is added to the amine, and/or the catechol functionality is either eliminated or masked as a way of making these compounds more stable.
  [FR] L'invention concerne de nouveaux composés s'utilisant comme agents d'imagerie dans le cadre d'applications de médecine nucléaire (imagerie PET) pour effctuer l'imagerie de l'innervation cardiaque. Ces radiotraceurs fondés sur la PET peuvent manifester une stabilité accrue, une diminution de la libération de NE (ce qui contribue à réduire les effets secondaires), de meilleures données quantitatives et/ou une affinité élevée pour le VMAT par rapport aux radiotraceurs antérieurs. L'invention concerne également des méthodes pour utiliser ces composés pour effectuer l'imagerie de l'innervation cardiaque. Dans certains cas, les composés sont obtenus par dérivation de certains composés marqués par ^{1 8}F